Adaptive Biotechnologies at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Adaptive Biotechnologies brings 1 presentation to ASH 2026 in New Orleans, and exhibits at Booth 3629. Its research centres on measuring residual disease in lymphoma. It covers validating the clonoSEQ test on cell-free DNA for large B-cell lymphoma.
| Organization | ASH 2026 Attendance |
|---|---|
Adaptive Biotechnologies Seattle, WA | |
Immune-sequencing company behind the clonoSEQ minimal residual disease test; also develops immune-based diagnostics and therapeutics. | Booth Exhibiting at Booth 3629 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm |
Find decision makers at Adaptive Biotechnologies
Tell us what you sell and we’ll find the people at Adaptive Biotechnologies most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction